Rigel Provides Pipeline Update

10/24/2013

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free